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Introduction
The Alma Ata declaration of 1978 encouraged the use of all available resources for primary healthcare and recommended that government should give high priority to using traditional health practices and incorporate proven traditional remedies into National Drug Policy and Regulations [1] . As much as 80% of people in developing world are said to depend on traditional medicines for primary healthcare [2] . Over the years, there has been worldwide recognition of the vital role of herbal medicines in healthcare [3, 4] . Unfortunately, most of the herbal medicines are poorly regulated and controlled in many countries. Nevertheless, there is a dearth of scientific proofs of effectiveness and safety of herbal preparations, which is required for marketing authorization [5, 6] .
Jobelyn
® , manufactured by Health Forever Products Ltd., Lagos, Nigeria, is a commercial herbal preparation from Sorghum bicolor leaf-sheaths which contains carbohydrates, protein, tannins, saponins and iron. It is claimed to stimulate rapid production of red blood cells and maintains the integrity of white blood cells even with the presence of viral or bacterial infections. Jobelyn ® is said to strengthen the immune system and thereby enhances body's defensive mechanisms. Unpublished studies revealed the anti-trypanosomal activities of the product and haematinic effects in laboratory animals. The manufacturers recommend it as remedy for anemia in sickle cell anemia, cancer, HIV/AIDS, malaria, typhoid fever, aplastic anemia and pregnancy. Preliminary pilot preclinical studies in mice showed that Jobelyn ® does not create significant adverse effects but it significantly lowered serum creatinine and cholesterol levels. However, unpublished toxicological evaluation of the product in mice has shown its lethal effects at high doses. Although Jobelyn ® is currently used by people in many countries, the clinical efficacy and safety have not been scientifically reported [7] . The main objective of this work was to evaluate its toxicity profiles after acute and short-term chronic administration.
Materials and Methods

Animals
Healthy albino mice (58 males and 50 females; average weight, 16.45 ±3.14 g; weight range 13.75 -19.48 g) were obtained from the Animal House of the College of Medicine, University of Lagos, Nigeria. The animals were kept in clean cages (10 mice/cage) in well-ventilated room and allowed unrestricted access to livestock feeds (from Ladokun feeds, Ibadan) and fresh water. They were also allowed to acclimatize to the environment for one week before each experiment. During this period of acclimatization, the animals were periodically assessed for gross morphological/behavioral changes. The animal cages were cleaned out of waste alternate days.
Acute toxicity testing
This was carried out to determine doseresponse effects, sub-lethal and lethal doses, and to calculate the LD 50 using both the oral and intraperitoneal routes Oral Route: 42 mice were divided into 7 equal groups (A -G). Mice in groups A to F were administered 6, 12, 18, 24, 30 and 42 ml/kg of 20% solution of JOBELYN® (8.2 mg/ml) orally. The animals in group G that served as control, were given 0.3 ml of deionized water orally.
Intra-peritoneal (IP) route: 36 mice were also divided into 6 equal groups (A -F). Mice in groups A to E were given 6, 12, 18, 24, 30 and 60 ml/kg of the stock solution of Jobelyn ® (8.2 mg/ml) intra-peritoneally whilst animals in group F, serving as control, received 0.3 ml of de-ionized water IP.
For each of the above routes, all the animals were monitored for gross morphological and behavioral changes (including changes in locomotor activity, pilo-erection, normal behavioral repertoire [grooming/licking/ biting], sedation, aggressiveness, catalepsy, appetite, urination, defecation, vomiting, sneezing/wheezing) over 72 hr and the LD 50 was determined using probit analysis within 95% confidence limit. The animals were then sacrificed and essential organs (preserved in 10% formaldehyde solution for 4 weeks before processing) subjected to histological examination for pathological changes. The various organs were processed using the automatic tissue processor. This technique involved dehydrating the well-fixed 3 mmsized tissues placed in tissue baskets with their respective labels by passing them through graded alcohol. They were then moved into xylene solution baths and then placed in molten wax for impregnation. The solidified blocks were trimmed and sectioned using the Rotary microtome at 5 ̩ µ thickness. Sections were then floated on water bath at 50 o C and picked up using albuminized microscopic slides. The cut sections were dried on hot plates at 60 o C and then stained by haematoxytocin and eosin to demonstrate tissue structures.
Sub-acute toxicity testing/short-term chronic toxicity
Thirty (30) mice were divided into three equal groups (A -C). Those in groups A and B were given 0.1 and 0.2 ml of 20% solution of JOBELYN® (8.2 mg/ml) IP daily for 2 weeks while those in group C (control) were given 0.3 ml de-ionized water intraperitoneally daily for the same period. The animals were monitored for morbidity and mortality (including changes in locomotor activity, piloerection, normal behavioral repertoire [grooming/licking/biting], sedation, aggressiveness, catalepsy, appetite, urination, defecation, vomiting, sneezing/wheezing), sacrificed after 15 days and essential organs (preserved in 10% formaldehyde solution for 4 weeks before processing) were examined histologically for pathological changes as described earlier.
Results
Acute toxicity testing
Following oral treatment of the animals, the observed changes in behavior of the animals is presented in Table 1 . The mortality rates and probit analysis report are recorded in Table 2 . Reduced mobility accompanied the administration of Jobelyn ® from the 0.3 ml dose level within 1 hr. However, the animals were alert, except at high doses where a slight degree of sedation was noted. There was also some degree of pilo-erection and the surviving animals recovered motility soon after 48 hr. The normal behavioral repertoire was maintained. There was no noticeable reduction in appetite or changes in urine output. The LD 50 values for oral route was found to be 215.06 (147.30 -313.99) mg/kg. The summary of observed behavioral changes following intraperitoneal administration of Jobelyn ® , mortality rates and probit analysis are presented in Tables 3  and 4 , respectively.
Short-Term Chronic Toxicity Testing
. The observed behavioral changes following the administration of 0.1ml and 0.2 ml of the stock solution of Jobelyn to 2 groups of ten mice each daily for 2 weeks are presented in Table 5 .
Histopathological examination revealed no marked pathological changes in the heart and kidneys but moderate congestion in the lungs and liver and slight congestion in the spleen at lethal doses.
Discussion
Most of the toxicological studies report that toxic effects due to the use of herbal medicine are associated with hepatotoxicity. Other toxic effects on the kidneys, nervous system, blood, and cardiovascular system, as well as medicinal herbs' mutagenicity and carcinogenicity have also been published in medical journals [5] . The true incidence of hepatic damage caused by herbal medications is unknown. In the case of Chinese herbal remedies, the incidence of hepatotoxicity has been estimated at between 0.2% and 1% [6] . No accurate estimate of the prevalence of herbal remedies in Africa has been reported.
The manufacturers of Jobelyn recommend as much as 500 mg per dose (2 capsules) and 1.5 g per day (6 capsules) for humans. For any average adult weighing 70 kg, the recommended doses translate to a dosage of about 7.14 mg/kg per dose and 21.42 mg/kg/day, which are much smaller than the LD 50 in this study. Even though the extrapolation of data from animals to humans is anticipated and not definitive, the recommended dosage regimen in man can be said to be comparatively very safe. For the oral route, the product has a tolerance limit of 99.70mg/kg. This gives a large room for dosage manipulation, which may be applicable to man.In this study, Jobelyn ® has been found to produce only toxic effects at high doses in the animals suggesting that Jobelyn is relatively safe when used at usual doses for a long time in the animals. Lethal consequences of the product may be expected in sufficiently high dosages.
Some behavioral changes in the animals (reduced motility and sedation) may not be mutually exclusive; i.e. one could be responsible for the other. These effects may also have been responsible for the seeming loss of appetite that was observed at high doses in this study. The eye irritation observed in the animals when the product was administred through the oral route is attributable to direct contact of the product with the eye during administration.
Conclusion
There are indications that Jobelyn could be safe in humans when used at at doses recommended by the manufacturers. However, further toxicological screening in Int J Health Res, December 2009; 2(4): 374 humans is required to ascertain the safety profile.
